CRISPR Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at StockNews.com to a "sell" rating.
Why Is CRISPR Therapeutics (CRSP) Up 0.4% Since Last Earnings Report? [Yahoo! Finance]
ElevateBio taps Amazon's genAI tools to design CRISPR therapeutics [Yahoo! Finance]
Global Genome Editing Market to Grow Rapidly at a CAGR ~13% by 2032 | DelveInsight [Yahoo! Finance]
CRISPR Market is expected to generate a revenue of USD 12.78 Billion by 2032, Globally, at 15.85% CAGR: Verified Market Research® [Yahoo! Finance]